5月25日，据CDE官网消息，上海盛迪医药有限公司、苏州盛迪亚生物医药有限公司联合申请药品“阿得贝利单抗注射液”，获得临床试验默示许可，受理号CXSL2500231。
公示信息显示，药品“阿得贝利单抗注射液”适应症：本品联合SHR-A1811＋苹果酸法米替尼用于实体瘤的治疗。
上海盛迪医药有限公司，成立于2014年，位于上海市，是一家以从事医药制造业为主的企业。企业注册资本25000万人民币，实缴资本25000万人民币。
通过天眼查大数据分析，上海盛迪医药有限公司共对外投资了2家企业，参与招投标项目31次，专利信息93条，此外企业还拥有行政许可55个。
主要股东信息显示，上海盛迪医药有限公司由江苏恒瑞医药股份有限公司持股100%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.